Highest-materiality recent filing
Mosaic to acquire Oncotelic's clinical necroptosis cancer assets for up to $30M in stock
Binding term sheet signed April 26, 2024; acquisition includes VDA necroptosis therapies and AI platform.
CWRU terminates Mosaic's CPMV license for lead candidate MIE-101 over ~$407K unpaid IP fees
Effective March 22, 2024, CWRU terminated the exclusive worldwide license agreement due to financial default.
On July 23, 2024, Mr. Carlton Johnson notified the Board of Directors (the “Board”) of Mosaic ImmunoEngineering, Inc. (the “Company”) of his resignation from the Board effective immediately.
Mr. Paul Lytle, EVP, Chief Financial Officer of the Company, agreed to amend Mr. Lytle’s employment terms from full time status to part time status, not to exceed eight (8) hours per month effective June 1, 2024
Mosaic ImmunoEngineering, Inc. (the “Company”) is deeply saddened to announce that director Ms. Gloria Felcyn passed away on April 17, 2024.
Max materiality 0.85 · Median 0.50 · Most common event leadership